BiomX
An Israel-based microbiome drug discovery company developing customized phage therapies that seek and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer.
BiomX discovers and validates proprietary bacterial targets and customizes its natural and engineered phage compositions against these targets.
The company's pipeline consists of four therapies for acne, inflammatory bowel disease, liver diseases and colorectal cancer.
The company’s platforms use computational and synthetic biology and research from professors Rotem Sorek, Eran Elinav, and Eran Segal of The Weizmann Institute of Science; and professor Timothy Lu of The Massachusetts Institute of Technology.
BiomX works in partnerships with Takeda, JSR Corporation and Janssen Pharmaceuticals.
Latest BiomX News & Features
2 April 2024
6 March 2024
16 October 2019
11 June 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze